Login to Your Account



Other News To Note


Friday, February 24, 2012
• Can-Fite BioPharma Ltd., of Petah-Tikva, Israel, said the FDA granted orphan drug status to CF102, its candidate in hepatocellular carcinoma (primary liver cancer). Last month, Can-Fite reported results of a Phase I/II study of CF102 suggesting the compound demonstrated a favorable safety profile in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis Classes A and B. The study also indicated the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict patient response to treatment. CF102 is an orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription